Novel polymeric micelles for drug delivery: Material characterization and formulation screening

Janas, Christine; Mostaphaoui, Zouhair; Schmiederer, Ludwig; Bauer, Johann; Wacker, Matthias G.

doi:10.1016/j.ijpharm.2016.05.029

Cited by 31 publications

(10 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, because of its poor solubility in water, the further application of DA has been restricted (Huang et al, 2016 ). Considering these drawbacks, a serial of micro/nanoparticle delivery-systems were developed to solve these problems (Park et al, 2012 ; Robinson et al, 2016 ; Janas et al, 2016 ). The objective of this study is to use a biodegradable polymer monomethyl poly(ethylene glycol)−poly(ɛ-caprolactone) (MPEG-PCL) as the delivery vehicle for DA to achieve the synergism between inhibiting lipid peroxidation and inflammation effects of the hydrophobic loaded drugs and sealing the damaged axonal membranes of the amphipathic delivery vehicle.…”

Section: Introductionmentioning

confidence: 99%

Effective improvement of the neuroprotective activity after spinal cord injury by synergistic effect of glucocorticoid with biodegradable amphipathic nanomicelles

Wang

et al. 2017

Drug Delivery

View full text Add to dashboard Cite

Dexamethasone acetate (DA) produces neuroprotective effects by inhibiting lipid peroxidation and inflammation by reducing cytokine release and expression. However, its clinical application is limited by its hydrophobicity, low biocompatibility and numerous side effects when using large dosage. Therefore, improving DA’s water solubility, biocompatibility and reducing its side effects are important goals that will improve its clinical utility. The objective of this study is to use a biodegradable polymer as the delivery vehicle for DA to achieve the synergism between inhibiting lipid peroxidation and inflammation effects of the hydrophobic-loaded drugs and the amphipathic delivery vehicle. We successfully prepared DA-loaded polymeric micelles (DA/MPEG-PCL micelles) with monodispersed and approximately 25 nm in diameter, and released DA over an extended period in vitro . Additionally, in the hemisection spinal cord injury (SCI) model, DA micelles were more effective in promoting hindlimb functional recover, reducing glial scar and cyst formation in injured site, decreasing neuron lose and promoting axon regeneration. Therefore, our data suggest that DA/MPEG-PCL micelles have the potential to be applied clinically in SCI therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Effective improvement of the neuroprotective activity after spinal cord injury by synergistic effect of glucocorticoid with biodegradable amphipathic nanomicelles

Wang

et al. 2017

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…In comparison to our systems, other polymeric micelles recently used for Dex encapsulation exhibited lower loading capacities. A loading capacity in the range 0.5–3% was observed for Dex-loaded micelles composed of poly(ethylene glycol) (PEG) as a hydrophilic part, and poly(butyl methacrylate) 53 , poly(D,L-lactide) 54 , poly(ε-caprolactone) (PCL) 55 , 56 and poly(propylene glycol) 57 , respectively, as a hydrophobic core. Slightly higher loading capacities (from 7 to 12%) were reported for PEG-PCL micelles loaded with Dex-acetate.…”

Section: Resultsmentioning

confidence: 99%

Investigation of drug release modulation from poly(2-oxazoline) micelles through ultrasound

Salgarella

Zahoranová

Šrámková

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Among external stimuli used to trigger release of a drug from a polymeric carrier, ultrasound has gained increasing attention due to its non-invasive nature, safety and low cost. Despite this attention, there is only limited knowledge about how materials available for the preparation of drug carriers respond to ultrasound. This study investigates the effect of ultrasound on the release of a hydrophobic drug, dexamethasone, from poly(2-oxazoline)-based micelles. Spontaneous and ultrasound-mediated release of dexamethasone from five types of micelles made of poly(2-oxazoline) block copolymers, composed of hydrophilic poly(2-methyl-2-oxazoline) and hydrophobic poly(2-n-propyl-2-oxazoline) or poly(2-butyl-2-oxazoline-co-2-(3-butenyl)-2-oxazoline), was studied. The release profiles were fitted by zero-order and Ritger-Peppas models. The ultrasound increased the amount of released dexamethasone by 6% to 105% depending on the type of copolymer, the amount of loaded dexamethasone, and the stimulation time point. This study investigates for the first time the interaction between different poly(2-oxazoline)-based micelle formulations and ultrasound waves, quantifying the efficacy of such stimulation in modulating dexamethasone release from these nanocarriers.

show abstract

“…Even though the highest achieved loading capacity is relatively low comparing to the POx and POzi formulations comprising CUR or PTX discussed above, it is still higher than DEXA formulations based on other block copolymers. [ 161–164 ] Interestingly, also other POx, including pBuOx and pPrOx containing block copolymers with lower DP and different ratio of blocks exhibited lower loading capacities toward DEXA [ 99 ] These effects of copolymer composition require deeper examination. The release of DEXA from the micelles was accelerated by using ultrasound (US) as an external stimulus, however, the study was performed only in vitro using dialysis cups.…”

Section: Poly(2‐oxazoline)‐based Nanoformulationsmentioning

confidence: 99%

Poly(2‐oxazoline)‐ and Poly(2‐oxazine)‐Based Self‐Assemblies, Polyplexes, and Drug Nanoformulations—An Update

Zahoranová

Luxenhofer

2021

Adv Healthcare Materials

View full text Add to dashboard Cite

For many decades, poly(2‐oxazoline)s and poly(2‐oxazine)s, two closely related families of polymers, have led the life of a rather obscure research topic with only a few research groups world‐wide working with them. This has changed in the last five to ten years, presumably triggered significantly by very promising clinical trials of the first poly(2‐oxazoline)‐based drug conjugate. The huge chemical and structural toolbox poly(2‐oxazoline)s and poly(2‐oxazine)s has been extended very significantly in the last few years, but their potential still remains largely untapped. Here, specifically, the developments in macromolecular self‐assemblies and non‐covalent drug delivery systems such as polyplexes and drug nanoformulations based on poly(2‐oxazoline)s and poly(2‐oxazine)s are reviewed. This highly dynamic field benefits particularly from the extensive synthetic toolbox poly(2‐oxazoline)s and poly(2‐oxazine)s offer and also may have the largest potential for a further development. It is expected that the research dynamics will remain high in the next few years, particularly as more about the safety and therapeutic potential of poly(2‐oxazoline)s and poly(2‐oxazine)s is learned.

show abstract

Novel polymeric micelles for drug delivery: Material characterization and formulation screening

Cited by 31 publications

References 50 publications

Effective improvement of the neuroprotective activity after spinal cord injury by synergistic effect of glucocorticoid with biodegradable amphipathic nanomicelles

Effective improvement of the neuroprotective activity after spinal cord injury by synergistic effect of glucocorticoid with biodegradable amphipathic nanomicelles

Investigation of drug release modulation from poly(2-oxazoline) micelles through ultrasound

Poly(2‐oxazoline)‐ and Poly(2‐oxazine)‐Based Self‐Assemblies, Polyplexes, and Drug Nanoformulations—An Update

Contact Info

Product

Resources

About